EP1292301A1 - Traitement et prevention des etats associes a l'insulino-resistance cardiaque - Google Patents

Traitement et prevention des etats associes a l'insulino-resistance cardiaque

Info

Publication number
EP1292301A1
EP1292301A1 EP00938933A EP00938933A EP1292301A1 EP 1292301 A1 EP1292301 A1 EP 1292301A1 EP 00938933 A EP00938933 A EP 00938933A EP 00938933 A EP00938933 A EP 00938933A EP 1292301 A1 EP1292301 A1 EP 1292301A1
Authority
EP
European Patent Office
Prior art keywords
insulin resistance
cardiac
heart failure
treatment
congestive heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00938933A
Other languages
German (de)
English (en)
Inventor
Ameet SmithKline Beecham Pharm. NATHWANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1292301A1 publication Critical patent/EP1292301A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to a novel treatment and in particular to a method for the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance.
  • Increases in insulin resistance represent an impairment in the normal biological response to insulin. It is usually associated with conditions such as Type 2 diabetes mellitus where the resistance is primarily manifest in skeletal muscle, adipose tissue and the liver. In certain circumstances however, insulin resistance presents in tissues and organs other than in skeletal muscle and liver and in particular can be present selectively in the heart as cardiac- insulin resistance. In diseases such as cardiac syndrome-X [a form of microvascular angina], or in patients with accelerated atherosclerosis or chronic heart-failure, the increased insulin resistance in the myocardium impairs the ability of the myocardium to rapidly and effectively utilise glucose for metabolism, and may further exacerbate the delicate metabolic balance in this critical tissue.
  • cardiac syndrome-X a form of microvascular angina
  • the increased insulin resistance in the myocardium impairs the ability of the myocardium to rapidly and effectively utilise glucose for metabolism, and may further exacerbate the delicate metabolic balance in this critical tissue.
  • EP 0306228 is 5-(4-[2-(N-methyl-N-(2- ⁇ yridyl)amino)ethoxy]benzyl)-2,4- thiazolidinedione (or 'Compound (1)0.
  • PPAR ⁇ peroxisome proliferator-activated receptor
  • USP 5521201 discloses that Compound (I) is useful in the treatment of cardiac disease especially athereosclerosis. Also WO 00/04889 discloses that Compound (I) is useful for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia.
  • Compound (I) has activity in the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance. It is therefore of potential use in the treatment or prophylaxis of microvascular angina, atherosclerosis associated with insulin resistance and in the treatment of congestive heart failure, especially in delaying the progression of congestive heart failure, ameliorating or reversing reductions in cardiac muscular endurance and strength associated with congestive heart failure and ameliorating and/or reversing the cachexic phase of congestive heart failure.
  • the invention provides a method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, in humans or non-human mammals, which method comprises the administration of an effective, non- toxic and pharmaceutically acceptable amount of a PPAR ⁇ agonist, such as Compound (I), or a pharmaceutically acceptable derivative thereof.
  • a PPAR ⁇ agonist such as Compound (I)
  • Particular conditions associated with cardiac insulin resistance include microvascular angina and congestive heart failure.
  • a further condition associated with cardiac insulin resistance is atherosclerosis associated with insulin resistance.
  • a suitable condition associated with cardiac insulin resistance is microvascular angina.
  • a suitable condition associated with cardiac insulin resistance is congestive heart failure.
  • the present treatment is particularly indicated to delay the progression of congestive heart failure, ameliorate and/or reverse reductions in cardiac muscular endurance and/or strength associated with congestive heart failure and ameliorate and/or reverse the cachexic phase of congestive heart failure.
  • the present treatment delays the progression of congestive heart failure.
  • the present treatment ameliorates and or reverses reductions in cardiac muscular endurance and/or strength associated with congestive heart failure.
  • the present treatment ameliorates and/or reverses the cachexic phase of congestive heart failure.
  • Suitable PPAR ⁇ agonists include thiazolidinediones, especially thiazolidine-2,4- diones, that is a compound comprising a moiety of formula (A):
  • Suitable compounds comprising a moiety of formula (a) include compounds of formula (I):
  • T represents an aryl or heterocyclyl group optionally substituted with one or more alkyl groups, aralkyl groups or heterocyclylalkyl groups, the said alkyl, aralkyl and heterocyclylalkyl groups themselves being optionally substituted.
  • the carbon atom marked with an asterisk (*) in formula (I) is a chiral carbon.
  • T represents a moiety selected from the list consisting of (a), (b), (c),
  • Thiazolidinedione PPAR ⁇ agonists may exist in one of several tautomeric forms, all of which are encompassed by the present invention as individual tautomeric forms or as mixtures thereof. Where a PPAR ⁇ agonist contains a chiral carbon, and hence exists in one or more stereoisomeric forms or where one or more geometric isomers exist, it will be appreciated that the method of the present invention encompasses all of the said forms of the PPAR ⁇ agonists whether as individual isomers or as mixtures of isomers, including racemates.
  • thiazolidinediones are those disclosed in EP 0306228 and WO94/05659. Further particular examples are the thiazolidinediones disclosed in EP0139421 and USP 5478852.
  • a preferred thiazolidinedione is Compound (I). Further particular thiazolidinediones are, (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8- tetramethyl-2H- 1 -benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(l-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone)
  • PPAR ⁇ agonist' relates to an agonist, such as a small molecular weight agonist, of the peroxisomal proliferator-activated receptor of the gamma subtype, this nuclear receptor is a member of the ligand activated transcription factor family that include the steroid, retinoid and thyroid receptors.
  • PPAR ⁇ agonist activity may be assessed by use of the methodology disclosed by Lehmann et al : Journal of Biological Chem., 270, 12953-12956 (1995).
  • 'aryl' includes phenyl and naphthyl optionally substituted with up to five, preferably up to three, groups selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxy, amino, nitro, carboxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.
  • Suitable heterocyclyl groups are aromatic and non-aromatic heterocylic groups.
  • Suitable non-aromatic heterocylic groups include groups comprising single or fused ring heterocyclic groups comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen, optionally fused to one or more aryl groups.
  • Suitable aromatic heterocyclyl groups include substituted or unsubstituted, single or fused ring aromatic heterocyclyl groups comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen.
  • Favoured aromatic heterocyclyl groups include substituted or unsubstituted single ring aromatic heterocyclyl groups having 5 to 7 ring atoms, preferably 5 or 6 ring atoms.
  • the aromatic heterocyclyl groups comprise 1, 2 or 3 heteroatoms, especially 1 or 2, selected from oxygen, sulphur or nitrogen.
  • Suitable substituents for the heterocyclyl include up to 4 substituents selected from the group consisting of: alkyl, alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, preferably a benzene ring, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted.
  • Tialogen' refers to fluorine, chlorine, bromine and iodine; preferably chlorine.
  • 'alkyl' and 'alkoxy' relate to groups having straight or branched carbon chains, containing up to 12 carbon atoms.
  • acyl' includes alkylcarbonyl groups.
  • Suitable alkyl groups are Cj- ⁇ alkyl groups, especially C ⁇ - alkyl groups e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl or tert-butyl groups.
  • Suitable substituents for any alkyl group include those indicated above in relation to the term "aryl”.
  • Suitable derivatives of a PPAR ⁇ agonist are pharmaceutically acceptable derivatives, for example salts and solvates.
  • Suitable derivatives of any particular PPAR ⁇ agonist include those disclosed in the above mentioned publications.
  • Suitable pharmaceutically acceptable salts include salts of salts derived from appropriate acids, such as acid addition salts, or bases.
  • Suitable pharmaceutically acceptable salts include metal salts, such as for example aluminium, alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy alkylamines such as 2-hydroxyethylamine, bis-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, cycloalkylamines such as bicyclohexylamine, or with procaine, dibenzylpiperidine, N-benzyl-b-phenethylamine, dehydroabietylamine, N,N'-bisdehydroabietylamine, glucamine, N-methylglucamine or bases of the pyridine type such as pyridine, collidine, quinine or quinoline.
  • metal salts such as for example aluminium, alkali metal salts such as lithium, sodium or potassium,
  • Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane-sulphonate, a-keto glutarate and a- glycerophosphate, especially the maleate salt.
  • pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide
  • pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methane-sulphonate, a-keto glutarate and a- glycerophosphate, especially the maleate salt.
  • Suitable pharmaceutically acceptable salts of Compound (I) are as disclosed in EP 0306228 and WO94/05659 and include maleate salts. . Suitable pharmaceutically acceptable solvates include hydrates.
  • Suitable pharmaceutically acceptable solvates of Compound (I) are as disclosed in EP 0306228 and WO94/05659 and include hydrates.
  • PPAR ⁇ agonists such as the thiazolidinediones, referred to herein are conveniently prepared according to the methods disclosed in the above mentioned patent publications in which they are disclosed:
  • Compound (I), or the tautomeric form thereof, and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof may be prepared using the processes described in EP 0306228 and WO94/05659.
  • salts and/or solvates of the thiazolidinediones may be prepared and isolated according to conventional procedures for example those disclosed in the, above mentioned, patent publications.
  • the present invention also provides a PPAR ⁇ agonist or a pharmaceutically acceptable derivative thereof, for use in the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance.
  • the present invention also provides a PPAR ⁇ agonist or a pharmaceutically acceptable derivative thereof, for use in the manufacture of a medicament for the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance.
  • the PPAR ⁇ agonist may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
  • the PPAR ⁇ agonist mentioned herein is formulated and administered in accordance with the methods disclosed in the above mentioned publications, patent applications and patents. Accordingly, the present invention also provides a pharmaceutical composition for the treatment and/or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, which composition comprises a PPAR ⁇ agonist, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier therefor.
  • the term 'pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
  • composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
  • compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.
  • compositions for oral administration are unit dosage forms such as tablets and capsules.
  • Other fixed unit dosage forms, such as powders presented in sachets, may also be used.
  • the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant or other conventional adjuvant.
  • Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulphate or sucrose.
  • Suitable dosages of the PPAR ⁇ agonist include the known doses for these compounds as described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Complete Drug Reference (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications or doses which can be determined by standard procedures.
  • Suitable dosages of the Compound (I) include those disclosed in EP 0306228 and WO94/05659 and 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg of Compound (I). .
  • Particular dosages of Compound (I) are 2mg, 4mg and 8mg.
  • Particular dosages of troglitazone include from 100 to 800mg such as 200, 400, 600 or 800mg.
  • Particular dosages of pioglitazone include from 5 to 50mg, including 10 to 40mg, such as 15, 20, 30 or 40 mg of pioglitazone.
  • the composition of the invention may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
  • composition of the invention may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
  • the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats
  • emulsifying agents for example lecithin, sorbitan monooleate, or
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
  • compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
  • the compositions are formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Complete Drug Reference (London, The Pharmaceutical Press) and Harry's Cosmeticology (Leonard Hill Books).
  • the activity of compounds in the treatment of the present invention can be determined using known methodology, for example by use of procedures disclosed by Eckel J, Asskamp,B, Reinauer, H (1991) Endocrinology 129, 345-352 Induction of insulin resistance in primary cultured adult cardiomyocytes. No adverse toxicological effects are expected for the compositions or methods of the invention in the above mentioned dosage ranges.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédé de traitement ou de prévention de l'insulino-résistance cardiaque ou des états associés à l'insulino-résistance cardiaque chez les mammaliens humains ou non humains, qui comprend l'administration d'une quantité efficace, non toxique et pharmaceutiquement acceptable d'un agoniste de PPARy tel que le composé (I) ou un dérivé pharmaceutiquement acceptable de celui-ci. Les états associés à l'insulino-résistance cardiaque sont l'angine microvasculaire, l'athérosclérose et l'insuffisance cardiaque globale. Les composés comprennent la rosiglitazone, la troglitazone, l'englitazone et la pioglitazone.
EP00938933A 2000-06-16 2000-06-16 Traitement et prevention des etats associes a l'insulino-resistance cardiaque Withdrawn EP1292301A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (fr) 2000-06-16 2000-06-16 Traitement et prevention des etats associes a l'insulino-resistance cardiaque

Publications (1)

Publication Number Publication Date
EP1292301A1 true EP1292301A1 (fr) 2003-03-19

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00938933A Withdrawn EP1292301A1 (fr) 2000-06-16 2000-06-16 Traitement et prevention des etats associes a l'insulino-resistance cardiaque

Country Status (15)

Country Link
EP (1) EP1292301A1 (fr)
JP (1) JP2004503499A (fr)
CN (1) CN1592620A (fr)
AP (1) AP2002002688A0 (fr)
BG (1) BG107384A (fr)
BR (1) BR0017254A (fr)
CA (1) CA2436116A1 (fr)
DZ (1) DZ3389A1 (fr)
EA (1) EA200300028A1 (fr)
HU (1) HUP0301103A2 (fr)
IL (1) IL153452A0 (fr)
MX (1) MXPA02012619A (fr)
NO (1) NO20026000L (fr)
WO (1) WO2001095906A1 (fr)
YU (1) YU1203A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
EP0930882A2 (fr) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention ou traitement de diabetes non insulinodependants ou de maladies cardiovasculaires avec des modulateurs ppar
WO1999059586A1 (fr) * 1998-05-19 1999-11-25 Regents Of The University Of California Derives de thiazolidine et d'oxazolidine pour le traitement d'infarctus du myocarde aigus et pour l'inhibition de l'apoptose des cardiomyocytes
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0195906A1 *

Also Published As

Publication number Publication date
DZ3389A1 (fr) 2001-12-20
HUP0301103A2 (hu) 2003-08-28
BR0017254A (pt) 2004-01-06
MXPA02012619A (es) 2003-04-10
EA200300028A1 (ru) 2003-04-24
AP2002002688A0 (en) 2002-12-31
JP2004503499A (ja) 2004-02-05
BG107384A (bg) 2003-09-30
NO20026000D0 (no) 2002-12-13
NO20026000L (no) 2003-02-11
IL153452A0 (en) 2003-07-06
YU1203A (sh) 2006-05-25
WO2001095906A1 (fr) 2001-12-20
CA2436116A1 (fr) 2001-12-20
CN1592620A (zh) 2005-03-09

Similar Documents

Publication Publication Date Title
US20070238757A1 (en) Novel treatment
EP1593379A2 (fr) Utilisations d'agonistes PPAR-gamma dans le traitement de maladies induites par les neutrophiles
EP0695183B1 (fr) Utilisation de thiazolidinediones pour le traitement de l'atherosclerose et des desordres de l'alimentation
WO2000076488A2 (fr) Nouveau traitement
US20040034067A1 (en) Novel method of treatment
EP1292301A1 (fr) Traitement et prevention des etats associes a l'insulino-resistance cardiaque
AU2000254153A1 (en) Treatment and prevention of cardiac insulin resistance associated conditions
ZA200300283B (en) Treatment and prevention of cardiac insulin resistance associated conditions.
OA12831A (en) Treatment and prevention of cardiac insulin resistance associated conditions.
KR20030019434A (ko) 심장 인슐린 내성 관련 증상의 치료 및 예방
CZ20024067A3 (cs) Léčivo pro léčení nebo profylaxi srdeční rezistence na insulin
US20040266833A1 (en) Novel use of certain insulin sensitizers or ppar-gamma agonists
AU1719600A (en) Novel method of treatment
AU781742B2 (en) Novel method of treatment
KR20010024482A (ko) 고혈당증 치료용 티아졸리딘디온의 용도
KR20010024481A (ko) 고혈당증 치료용 티아졸리딘디온의 용도
CZ7799A3 (cs) Farmaceutický prostředek proti leptinové rezistenci
AU4586902A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
AU2005200702A1 (en) Novel method of treatment
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1055245

Country of ref document: HK